CA2397537C - External plaster containing 4-biphenylyl acetic acid - Google Patents
External plaster containing 4-biphenylyl acetic acid Download PDFInfo
- Publication number
- CA2397537C CA2397537C CA002397537A CA2397537A CA2397537C CA 2397537 C CA2397537 C CA 2397537C CA 002397537 A CA002397537 A CA 002397537A CA 2397537 A CA2397537 A CA 2397537A CA 2397537 C CA2397537 C CA 2397537C
- Authority
- CA
- Canada
- Prior art keywords
- weight
- base material
- bpaa
- adhesive base
- external plaster
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/21—Acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
Abstract
An aqueous hot melted type adhesive base material containing 4-biphenylyl acetic acid (BPAA) is provided. The adhesive base material contains constant amounts of BPAA and has good drug releasability, so that bioavailability of the drug is enhanced. An analgesic and anti-inflammatory external plaster containing BPAA is also provided. The plaster is obtained by dissolving BPAA into an aqueous hot melted type adhesive base material comprising as essential components a styrene-isoprene-styrene block copolymer, an adhesive resin, an antioxidant, lanolin, and water.
Description
SPECIFICATION
TECHNICAL FIELD
The present invention relates to plasters containing 4-biphenylyl acetic acid (general name: FELBINAC; hereinafter simply referred as to "BPAA"), and more particularly, to analgesic and anti-inflammatory external plasters in which BPAA is dissolved into an aqueous hot melted type adhesive base material comprising a styrene-isoprene-styrene block copolymer, an adhesive resin, an antioxidant, lanolin, and water as essential components.
BACKGROUND ART
BPAA is a pharmacologically active agent that is widely used in various external preparations, such as ointments, lotions, and aqueous plasters (cataplasm), for the purposes of relieving pain and alleviating inflammation in various disease conditions, including osteoarthritis, muscle- and fascia-related lumbago, periarthritis humeroscapularis, tendinitis, tenosynovitis, peritendinitis, external humeral epicondylitis (such as tennis elbow), sore muscle, and post-traumatic swelling and pain.
Among these external preparations, ointments and lotions have been considered less suitable for administration of BPAA
continuously and in constant dosages and are also thought to be inconvenient since they may stick elsewhere other than the intended application site, and may sometimes soil the clothes at the time of administration. On the other hand, an aqueous plaster, though not associated with these problems, has a low adhesiveness and thus requires fixing means such as a strip of surgical tape so that it stays on flextion parts such as elbows and knees.
Non-aqueous adhesives are also known, including those that use natural or synthetic rubber as a base material and plasters that make use of adhesive base material using acrylate adhesive base. This type of plaster has a strong adhesiveness and is thought to overcome the drawbacks of aqueous plasters. Thus, much effort has been put into development of external preparations of various drugs using such plasters.
However, the low solubility of BPAA makes it difficult to dissolve BPAA directly in adhesive base material. BPAA is readily soluble in dimethylacetamide, less soluble in acetone, ethanol, glacial acetic acid, and ether, and hardly soluble in water. BPAA
is also hardly soluble in polyols, glycols, and esters, which are commonly used as a solvent for drugs in preparation of external plasters.
For this reason, attempts have been made to use various solubilizers to dissolve BPAA. For example, Japanese Patent Laid-Open Publication No. Hei 4-321624 discloses a technique in which crotamiton is used as a solubilizer for BPAA. Nonetheless, the use of crotamiton as a solubilizer to help dissolve BPAA has achieved a solubility of at most about 7%. Also, the solubility achieved by the aforementioned aqueous plaster, which uses diisopropanolamine as the solubilizer, is not more than about 11%.
Thus, it has been difficult heretofore, even with the help of a solubilizer, to obtain a hot melted type adhesive base material that contains BPAA in an amount sufficient to allow it to exert desired pharmacological effects.
In aqueous plasters containing BPAA, BPAA is solubilized by first dissolving diisopropanolamine in water so that it becomes ionized and then adding BPAA to the solution, thus facilitating dissolving of BPAA in the solution. Though possible, adoption of this technique in producing non-aqueous adhesives containing BPAA, for example, solvent adhesives, which require a drying process, or hot melted type adhesive base materials, which require exposure to high temperature, may result in evaporation of moisture and thus crystallization of BPAA in the adhesive base.
A surfactant may also be used as a component of the hot melted type adhesive base material in order to facilitate mixing of water. This approach, however, may cause skin irritation and thus is not favorable.
Aside from the above-described approaches, a water-absorbable or water-soluble high molecular compound is thought to enable the adhesive material to absorb water. One disadvantage of this approach is that moisture evaporates when the temperature is raised to melt the successive adhesive in continuous production.
As a result, the high molecular compound crystallizes and forms unwanted particles in the adhesive base. Moreover, water is surrounded by the high molecular compound which is presented in the adhesive base material, and this prevents diffusion of BPAA in the adhesive preparation, and as a result, the efficiency of drug utilization is lowered.
Accordingly, it is an objective of the present invention to provide an aqueous hot melted type adhesive base material containing BPAA that overcomes the above-identified problems.
This adhesive base material contains constant amounts of BPAA and exhibits a good releasability of the drug from the adhesive, thereby enhancing bioavailability of the drug.
SUMMARY OF THE INVENTION
The present invention has been devised to overcome the above-described problems and provides in one aspect an analgesic and anti-inflammatory external plaster containing 4-biphenylyl acetic acid as active ingredient, wherein 4-biphenylyl acetic acid is dissolved into an aqueous hot melted type adhesive base material comprising styrene-isoprene-styrene block copolymer, an adhesive resin, an antioxidant, lanolin, and water as essential components of said adhesive base material.
More specifically, the present invention provides an analgesic and anti-inflammatory external plaster containing BPAA, obtainable through the process comprising the steps of melting and kneading a styrene-isoprene-styrene block copolymer, an adhesive resin, an antioxidant, lanolin, and a softener to form an adhesive base material; adding water and an aqueous solution of BPAA to the adhesive base material at a temperature of 80 to 100 C, while stirring, to form an adhesive base material containing BPAA;
coating said base material on a liner; laminating the liner to a backing; and cutting the resulting backing to a desired size.
In one preferred embodiment of the present invention, the analgesic and anti-inflammatory plaster for external use containing BPAA contains water in an amount of 0.1 to 30%.
In a further aspect, the present invention provides an analgesic and anti-inflammatory external plaster containing BPAA
in which BPAA is dissolved into the above-described aqueous hot melted type adhesive base material in a stable manner.
In summary, what is characteristic of the present invention resides in the use of the aqueous hot melted type adhesive base material that contains a styrene-isoprene-styrene block copolymer, an adhesive resin, an antioxidant, lanolin and water as essential components. The plaster obtained by dissolving BPAA in such aqueous hot melted type adhesive base material has an enhanced drug stability as well as an enhanced drug releasability over time and thus overcomes the aforementioned drawbacks of the conventional art.
BEST MODE FOR CARRYING OUT THE INVENTION
An external plaster in accordance with the present invention will now be described in detail with the emphasis on the types and the amounts of the components contained.
Styrene-isoprene-styrene block copolymer (hereinafter referred simply as to "SIS") for use in the plaster of the present invention is synthetic rubber to form the basic component of the adhesive base material and has ratio of styrene/rubber as 14/86.
TECHNICAL FIELD
The present invention relates to plasters containing 4-biphenylyl acetic acid (general name: FELBINAC; hereinafter simply referred as to "BPAA"), and more particularly, to analgesic and anti-inflammatory external plasters in which BPAA is dissolved into an aqueous hot melted type adhesive base material comprising a styrene-isoprene-styrene block copolymer, an adhesive resin, an antioxidant, lanolin, and water as essential components.
BACKGROUND ART
BPAA is a pharmacologically active agent that is widely used in various external preparations, such as ointments, lotions, and aqueous plasters (cataplasm), for the purposes of relieving pain and alleviating inflammation in various disease conditions, including osteoarthritis, muscle- and fascia-related lumbago, periarthritis humeroscapularis, tendinitis, tenosynovitis, peritendinitis, external humeral epicondylitis (such as tennis elbow), sore muscle, and post-traumatic swelling and pain.
Among these external preparations, ointments and lotions have been considered less suitable for administration of BPAA
continuously and in constant dosages and are also thought to be inconvenient since they may stick elsewhere other than the intended application site, and may sometimes soil the clothes at the time of administration. On the other hand, an aqueous plaster, though not associated with these problems, has a low adhesiveness and thus requires fixing means such as a strip of surgical tape so that it stays on flextion parts such as elbows and knees.
Non-aqueous adhesives are also known, including those that use natural or synthetic rubber as a base material and plasters that make use of adhesive base material using acrylate adhesive base. This type of plaster has a strong adhesiveness and is thought to overcome the drawbacks of aqueous plasters. Thus, much effort has been put into development of external preparations of various drugs using such plasters.
However, the low solubility of BPAA makes it difficult to dissolve BPAA directly in adhesive base material. BPAA is readily soluble in dimethylacetamide, less soluble in acetone, ethanol, glacial acetic acid, and ether, and hardly soluble in water. BPAA
is also hardly soluble in polyols, glycols, and esters, which are commonly used as a solvent for drugs in preparation of external plasters.
For this reason, attempts have been made to use various solubilizers to dissolve BPAA. For example, Japanese Patent Laid-Open Publication No. Hei 4-321624 discloses a technique in which crotamiton is used as a solubilizer for BPAA. Nonetheless, the use of crotamiton as a solubilizer to help dissolve BPAA has achieved a solubility of at most about 7%. Also, the solubility achieved by the aforementioned aqueous plaster, which uses diisopropanolamine as the solubilizer, is not more than about 11%.
Thus, it has been difficult heretofore, even with the help of a solubilizer, to obtain a hot melted type adhesive base material that contains BPAA in an amount sufficient to allow it to exert desired pharmacological effects.
In aqueous plasters containing BPAA, BPAA is solubilized by first dissolving diisopropanolamine in water so that it becomes ionized and then adding BPAA to the solution, thus facilitating dissolving of BPAA in the solution. Though possible, adoption of this technique in producing non-aqueous adhesives containing BPAA, for example, solvent adhesives, which require a drying process, or hot melted type adhesive base materials, which require exposure to high temperature, may result in evaporation of moisture and thus crystallization of BPAA in the adhesive base.
A surfactant may also be used as a component of the hot melted type adhesive base material in order to facilitate mixing of water. This approach, however, may cause skin irritation and thus is not favorable.
Aside from the above-described approaches, a water-absorbable or water-soluble high molecular compound is thought to enable the adhesive material to absorb water. One disadvantage of this approach is that moisture evaporates when the temperature is raised to melt the successive adhesive in continuous production.
As a result, the high molecular compound crystallizes and forms unwanted particles in the adhesive base. Moreover, water is surrounded by the high molecular compound which is presented in the adhesive base material, and this prevents diffusion of BPAA in the adhesive preparation, and as a result, the efficiency of drug utilization is lowered.
Accordingly, it is an objective of the present invention to provide an aqueous hot melted type adhesive base material containing BPAA that overcomes the above-identified problems.
This adhesive base material contains constant amounts of BPAA and exhibits a good releasability of the drug from the adhesive, thereby enhancing bioavailability of the drug.
SUMMARY OF THE INVENTION
The present invention has been devised to overcome the above-described problems and provides in one aspect an analgesic and anti-inflammatory external plaster containing 4-biphenylyl acetic acid as active ingredient, wherein 4-biphenylyl acetic acid is dissolved into an aqueous hot melted type adhesive base material comprising styrene-isoprene-styrene block copolymer, an adhesive resin, an antioxidant, lanolin, and water as essential components of said adhesive base material.
More specifically, the present invention provides an analgesic and anti-inflammatory external plaster containing BPAA, obtainable through the process comprising the steps of melting and kneading a styrene-isoprene-styrene block copolymer, an adhesive resin, an antioxidant, lanolin, and a softener to form an adhesive base material; adding water and an aqueous solution of BPAA to the adhesive base material at a temperature of 80 to 100 C, while stirring, to form an adhesive base material containing BPAA;
coating said base material on a liner; laminating the liner to a backing; and cutting the resulting backing to a desired size.
In one preferred embodiment of the present invention, the analgesic and anti-inflammatory plaster for external use containing BPAA contains water in an amount of 0.1 to 30%.
In a further aspect, the present invention provides an analgesic and anti-inflammatory external plaster containing BPAA
in which BPAA is dissolved into the above-described aqueous hot melted type adhesive base material in a stable manner.
In summary, what is characteristic of the present invention resides in the use of the aqueous hot melted type adhesive base material that contains a styrene-isoprene-styrene block copolymer, an adhesive resin, an antioxidant, lanolin and water as essential components. The plaster obtained by dissolving BPAA in such aqueous hot melted type adhesive base material has an enhanced drug stability as well as an enhanced drug releasability over time and thus overcomes the aforementioned drawbacks of the conventional art.
BEST MODE FOR CARRYING OUT THE INVENTION
An external plaster in accordance with the present invention will now be described in detail with the emphasis on the types and the amounts of the components contained.
Styrene-isoprene-styrene block copolymer (hereinafter referred simply as to "SIS") for use in the plaster of the present invention is synthetic rubber to form the basic component of the adhesive base material and has ratio of styrene/rubber as 14/86.
5 While adhesive base materials containing SIS are normally produced by melting at temperatures of 120 to 160 C, it is essential to design the production process of the aqueous hot melted type adhesive base material of the present invention so that the components are kneaded and mixed at 80 to 100 C in order to permit mixing of water.
It is thus preferred that the amount of SIS to be used is from 10 to 30% (as measured in t by weight with respect to the total weight of the adhesive preparation containing BPAA. All of the numbers expressed in percentages appear in the following description are calculated in the same manner.), more preferably from 15 to 25%. If the amount is less than 10%, the cohesion of the adhesive material is lost and it tends to remain on the surface to which it is applied after the plaster has been removed.
In comparison, if the amount exceeds 30%, the adhesive base material becomes hard, making kneading and mixing of the adhesive base material difficult. As a result, the adhesion of the base material is reduced.
Adhesion resin for use in the plaster of the present invention may be any of the following resin materials: aromatic resins such as Petrosin (manufactured by MITSUI PETROCHEMICAL
INDUSTRIES, Ltd.) and Hiresin (manufactured by TOHO OIL Co., Ltd.); aliphatic resins such as Escorez (manufactured by TONEN
OIL Co., LTD.) and Quintone (manufactured by NIPPON ZEON
Corporation); alicyclic petroleum resins; rosin resins; rosin ester resins; and terpene resins.
The amount of the adhesive resin to be used is preferably from 15 to 35%, and more preferably from 20 to 30%. If the amount is less than 15%, then the adhesive base material can hardly exhibit the adhesion, and the cohesion of the adhesive base material is reduced. As a result, the base material tends to remain on the surface to which it is applied after the plaster has been removed. In comparison, if the amount exceeds 35%, the adhesive base material becomes hard, making kneading and mixing of the adhesive difficult. As a result, the adhesiveness of the base material is reduced.
Antioxidant for use in the plaster of the present invention is contained for the purpose of preventing the adhesive base material from undergoing deterioration due to oxidation during mixing and storage of the adhesive base material. Examples of the antioxidant include dibutylhydroxytoluene, pentaerythrityl-tetrakis[3-(3,5-di-t-butyl-4-hysiroxyphenyl)]propionate, and tocopherol acetate. Preferably, these antioxidants are added in an amount of 0.1 to 2%.
Lanolin for use in the plaster of the present invention is also called "wool fat" and is purified and collected when secretions of sheep are washed off of wool. Lanolin is a cholesterin fat that does not lose its ointment-like viscosity even when added with 2 to 3 times as much water and is readily soluble in ether, chloroform, petroleum, benzine, or the like.
What is characteristic of the plaster of the present invention resides in the use of lanolin as a component of the adhesive base material for the plaster. Lanoline is blended to serve not only to retain moisture in the adhesive base material but also as a softener of the adhesive base material.
The amount of lanolin to be used is determined based on the balance between the amount of water and the amounts of other oils and fats and the softeners such as liquid rubbers. Preferably, the amount of lanolin is from 5 to 40% and more preferably from 10 to 30%. Lanolin contained in an amount less than 5% is insufficient for stable retention of water, whereas when contained in an amount greater than 40%, it makes the adhesive base material unfavorably sticky.
Water is contained for the purposes of dissolving BPAA and providing the base material with a sense of "cooling effect". The amount of water is determined based on the balance between the amount of the active ingredient and the amount of lanolin and is preferably from 0.1 to 30% and more preferably from 0.3 to 20%.
If the amount of water is less than 0.1%, it becomes difficult not only to dissolve BPAA in the base material but also to provide the "cooling effect" to the plaster. In comparison, the adhesive preparation can hardly have required properties if the amount of water exceeds 30%.
The plaster of the present invention may optionally contain a solubilizer for BPAA, including amines and crotamiton. Examples of amine include monoethanolamine, diethanolamine, diisopropanolamine, triethanolamine, and triisopropanolamine. The amount of amine to be contained is preferably in the range from 1 to 15%.
In addition, the plaster of the present invention may further contain a softener for the purpose of providing the adhesive base material with a proper plasticity. Aside from the above-described lanolin component, examples of the softener include liquid rubbers, liquid paraffin, and fatty acid esters including isopropyl myristate. The amount of the softener to be used is preferably from 5 to 50% and more preferably from 10 to 45%.
Less than 5% of the softener is insufficient to provide sufficient plasticity to the adhesive base material. In such a case, the base material becomes too hard to be spread. In comparison, the softener, if contained in an amount exceeding 50%, makes the adhesive base material unfavorably sticky and brings about unfavorable situations such as the base material remaining on the surface to which it is applied after the plaster has been removed, or the base material coming out from the edges of the backing.
The amount of BPAA for serving as the active ingredient in the plaster of the present invention is preferably from 0.5 to 8%
and more preferably from 2 to 6%. The amount of BPAA that is less than 0.5% is insufficient to elicit pharmacological effects of BPAA, whereas if the amount exceeds 8%, unfavorable situations arise, such as crystallizing of BPAA.
Aside from the above-described components, the adhesive base material of the present invention may contain a pharmaceutically acceptable absorption enhancer, refrigerant, preservative, bactericide, pigment and other pharmaceutically acceptable agents as desired.
Using the above-described adhesive components, the plaster of the present invention can be manufactured, for example, through the following process.
For example, SIS, the adhesive resin, the antioxidant, lanolin, and the softener are melted, mixed, and kneaded in a kneader heated to about 150 C to obtain the adhesive base material, which is then cooled to 80 to 100 C by air or water.
Subsequently, warm water, together with a BPAA solution (aqueous) to serve as the active ingredient solution, is added gradually to the adhesive base material under stirring. The resulting adhesive base material is spread on the liner to a predetermined thickness, and then, laminated with the backing.
Then, the backing thus obtained is cut into desired size to produce the plaster of the present invention.
Alternatively, the adhesive base material may be prepared in a separate container and is stored into block forms. A required amount of the block forms is then melted at 80 to 100 C and mixed with water and the active ingredient solution.
If the temperature of the adhesive base material exceeds 100 C during addition of the aqueous solution of the active ingredient and water, water is brought to boiling and evaporates, and as a result, the amount of water in the plaster is significantly reduced. In comparison, if the temperature is lower than 80 C, the adhesive base material becomes so viscous that it is difficult to stir the mixture during the addition of the aqueous solution of the active ingredient. This prevents uniform dispersion of the active ingredient.
Examples The present invention will be further illustrated by the following examples. It is to be understood that the present invention is not limited to these examples. Details may be deleted, added, or substituted as it is deemed to be appropriate, so long as the pharmacological activities of the plaster of the present invention is not changed. Such changes are also covered within the technical scope of the present invention.
Examples 1 to 8 Adhesive base material with formulations shown in Tables 1 and 2 below were prepared.
A sheet of polyester film treated with silicone was used to serve as a liner, and a piece of fabric made from polyester fiber was used to serve as a backing for each adhesive base material.
The amount of each adhesive base material coated was 100g/m2.
Table 1: Formulations of adhesive base material containing BPAA
Materials Ex. 1 Ex. 2 Ex. 3 Ex. 4 SIS 14.0 18.0 16.0 17.0 Saturated alicyclic petroleum resin 25.0 - - -Rosin ester resin - 22.0 - -Terpene resin - - 24.0 25.0 Polybutene - - 7.0 19.0 Liquid paraffin 13.0 6.0 17.0 8.0 Polyethyleneglycol-400 - - 10.0 5.0 Dibutylhydroxytoluene 1.0 1.0 1.0 1.0 Lanolin 24.0 25.0 10.0 10.0 Purified water 9.0 9.0 1.0 1.0 Purified water (solvent for the BPAA) 1.0 1.0 1.0 1.0 Diisopropanolamine 5.0 5.0 5.0 5.0 Crotamiton 2.5 2.5 2.5 2.5 BPAA 5.0 5.0 5.0 5.0 1-menthol 0.5 0.5 0.5 0.5 Isopropyl myristate - 5.0 - -Table 2: Formulations of adhesive base material containing BPAA
Materials Ex. 5 Ex. 6 Ex. 7 Ex. 8 SIS 16.0 10.0 30.0 10.0 Terpene resin 24.0 35.0 15.0 18.0 Polybutene 6.0 12.0 16.5 -Liquid paraffin - 10.5 5.0 -Polyethyleneglycol-400 - 1.0 - -Dibutylhydroxytoluene 1.0 1.0 1.0 1.0 Lanolin 25.0 5.0 10.0 40.0 Purified water 9.0 4.0 4.0 29.0 Purified water (solvent for BPAA) 1.0 1.0 1.0 1.0 Diisopropanolamine 10.0 3.0 5.0 0.5 Crotamiton 2.5 2.0 2.0 -BPAA 5.0 5.0 5.0 0.5 1-menthol 0.5 0.5 0.5 -Cetyl alcohol - 10.0 5.0 -Comparative Examples 1 to 4 As Comparative Examples, external plaster using water-free ----- - ------hot melted type adhesives base material and commercially available acrylic acid ester adhesives were prepared. Formulation for each Comparative Example is shown in Table 3 below.
Table 3: Formulations of adhesive base material for Comparative Exam les Materials Comp. 1 Comp. 2 Comp. 3 Comp. 4 SIS 18.0 20.0 - -Terpene resin 29.0 31.0 - -Polybutene 15.0 15.0 - -Liquid paraffin 9.0 15.0 - -Polyethyleneglycol-400 5.0 5.0 5.0 5.0 Dibutylhydroxytoluene 1.0 1.0 - -Acrylic adhesive A *1 - - 72.0 -Acrylic adhesive B *2 - - - 72.0 Lanolin 10.0 10.0 10.0 Diisopropanolamine 5.0 5.0 5.0 5.0 Crotamiton 2.5 2.5 2.5 2.5 BPAA 5.0 5.0 5.0 5.0 1-menthol 0.5 0.5 0.5 0.5 *1: 2-ethylhexyl acrylate / vinyl acetate copolymer (commercially available) *2: 2-ethylhexyl acrylate / vinyl pyrrolidone copolymer (commercially available) Test Example 1: Drug Permeability Test Using a commercially available aqueous BPAA plaster (cataplasm) as a control, above-prepared plasters of Examples and Comparative Examples were tested for the ability to permeate the drug component in the in vi tro skin permeability tests.
Methods:
Using a scalpel and scissors, a piece of abdominal skin was cut from a hairless rat and was mounted on a vertically placed Franz diffusion cell with the receptor compartment filled with saline. Warm water with a temperature of about 35 C was circulated through the jacket of the cell.
The above-prepared plasters were each applied to the skin of hairless rat, and the receptor solution was sampled over time for each plaster. The amount of the drug permeated in 24 hours was determined by HPLC.
Results:
The results of the tests are shown in Table 4. For the commercially available aqueous BPAA plaster (cataplasm) serving as the control, the amount of the permeated drug was 66.Oig/cm2.
Table 4: Results of rat skin permeability test Plaster No. Ex. 1 Ex. 2 Ex. 3 Ex. 4 ---- ---------------------------------- -----------------Amount permeated ig/cm2 58.2 74.6 62.4 81.5 Plaster No Ex. 5 Ex. 6 Ex. 7 Ex. 8 ---- -----------------------------------------------------Amount permeated i.g/cm2 65.8 55.3 84.2 65.0 Plaster No Comp. 1 Comp. 2 Comp. 3 Comp. 4 --- -------- ----- ----Amount permeated ig/cm2 29.8 21.5 43.7 31.6 As can be seen from the results of Table 4 above, the plaster of Examples of the present invention each exhibited higher skin permeability than the plaster of Comparative Examples. This indicates that the plaster of the present invention has an improved releasability of the drug.
Test Example 2: Stability Test The above-prepared plasters of Examples and Comparative Examples were each placed in a polyethylene-aluminum bag, were stored for 6 months at 40 C, and were then examined for the presence of crystal deposition.
No crystal deposition was observed on the plasters of Examples, whereas crystals formed on the plasters of Comparative Examples as early as after 1 month, causing the plasters to remain stuck to the liner or significantly reducing the adhesion. No decrease was observed in the amount of the active ingredient (BPAA) in any of the preparations.
The presence or the absence of crystal deposition on the plasters observed after the storage period was shown in Tables 5 through 7, with the results of the adhesive strength of the plasters.
The adhesive strength (unit = g/25mm) was measured by peeling the plaster from a Bakelite plate at 1800 angles.
Table 5: Results of stability test (Examples 1 to 4) Ex. 1 Ex. 2 Ex. 3 Ex. 4 Initial _ _ Crystal _ _ _ _None _ _ _ _ _None_ _ _ _ _None_ _ _ _None_ _ (after production) Adhesive stren th 780 890 540 690 40 C Crystal None None None None !--------- ------------ --------------- ------------- -------------1 month Adhesive stren th 750 870 610 710 40 C Crystal None None None None 3 months --Adhesive -- 760 890 590 ---- 680 stren th 40 C Crystal None None None None 6 months Adhesive-- -740 ----790-----620 ----690--stren strength Table 6: Results of stability test (Examples 5 to 8) Ex. 5 Ex. 6 Ex. 7 Ex. 8 Initial Crystal _ _ _ None _ _ _ _ _None _ _ _ _None_ _ _ _None_ _ (after production) Adhesive 750 480 360 100 stren th 40 C Crystal None __ None __ None __ None _ F_-_-_-_-_ _-_-_-_-_ _-_-_-_-_-_-_ _-_-_-_-_-_ _--_-_-_-_ 1 month Adhesive stren th 770 500 410 120 40 C Crystal None None None None r --Adhesive ---------------------------3 months stren th 730 490 400 90 40 C Crystal None None None None months --Adhesive-- --750 ----- 480 ----- 390 -----90 --6 stren th Table 7: Results of stability test (Comparative Examples 1 to 4) Comp. 1 Comp. 2 Comp. 3 Comp. 4 Initial Crystal _ _ _None _ None _ _ None _ _ None _ ----- -- ------ ----------- ------------ ----------(after production) Adhesive stren th 2340 1780 2540 1520 40 C Crystal formed formed formed Formed - -Adh --- -------------- ------------- --------------- --------------1 month esive stren th 1580 320 410 280 400 C Crystal _ _f_ormed_ _ _f_ormed_ _ _ _f_ormed_ _ _ F_orme_d_ 3 months Adtiesive stren th 1460 380 340 250 40 C Crystal formed _ formed __ formed __ Formed_ - - - - ----------- ------------ ----------6 months Adhesive 1390 350 390 280 stren th 11 As can be seen from the results of Tables 5 to 7, BPAA did not crystallize from the layer of the adhesive base material in any of the plaster of Examples of the present invention. Also, little change was observed in the adhesive strength in the plaster of Examples.
In contrast, deposition of BPAA crystals was observed in each of the plaster of Comparative Examples. These plaster lost adhesive strength significantly over time, failing to maintain their initial adhesion strength.
INDUSTRIAL APPLICABILITY
As mentioned above, the plaster for external use of the present invention, which is obtained by dissolving BPAA into an aqueous hot melted type adhesive base material comprising as essential components a styrene-isoprene-styrene block copolymer, an adhesive resin, an antioxidant, lanolin, and water, is advantageous in that it exhibits a good drug stability as well as a good drug releasability over time and the adhesion of the plaster is not decreased over time.
It is thus preferred that the amount of SIS to be used is from 10 to 30% (as measured in t by weight with respect to the total weight of the adhesive preparation containing BPAA. All of the numbers expressed in percentages appear in the following description are calculated in the same manner.), more preferably from 15 to 25%. If the amount is less than 10%, the cohesion of the adhesive material is lost and it tends to remain on the surface to which it is applied after the plaster has been removed.
In comparison, if the amount exceeds 30%, the adhesive base material becomes hard, making kneading and mixing of the adhesive base material difficult. As a result, the adhesion of the base material is reduced.
Adhesion resin for use in the plaster of the present invention may be any of the following resin materials: aromatic resins such as Petrosin (manufactured by MITSUI PETROCHEMICAL
INDUSTRIES, Ltd.) and Hiresin (manufactured by TOHO OIL Co., Ltd.); aliphatic resins such as Escorez (manufactured by TONEN
OIL Co., LTD.) and Quintone (manufactured by NIPPON ZEON
Corporation); alicyclic petroleum resins; rosin resins; rosin ester resins; and terpene resins.
The amount of the adhesive resin to be used is preferably from 15 to 35%, and more preferably from 20 to 30%. If the amount is less than 15%, then the adhesive base material can hardly exhibit the adhesion, and the cohesion of the adhesive base material is reduced. As a result, the base material tends to remain on the surface to which it is applied after the plaster has been removed. In comparison, if the amount exceeds 35%, the adhesive base material becomes hard, making kneading and mixing of the adhesive difficult. As a result, the adhesiveness of the base material is reduced.
Antioxidant for use in the plaster of the present invention is contained for the purpose of preventing the adhesive base material from undergoing deterioration due to oxidation during mixing and storage of the adhesive base material. Examples of the antioxidant include dibutylhydroxytoluene, pentaerythrityl-tetrakis[3-(3,5-di-t-butyl-4-hysiroxyphenyl)]propionate, and tocopherol acetate. Preferably, these antioxidants are added in an amount of 0.1 to 2%.
Lanolin for use in the plaster of the present invention is also called "wool fat" and is purified and collected when secretions of sheep are washed off of wool. Lanolin is a cholesterin fat that does not lose its ointment-like viscosity even when added with 2 to 3 times as much water and is readily soluble in ether, chloroform, petroleum, benzine, or the like.
What is characteristic of the plaster of the present invention resides in the use of lanolin as a component of the adhesive base material for the plaster. Lanoline is blended to serve not only to retain moisture in the adhesive base material but also as a softener of the adhesive base material.
The amount of lanolin to be used is determined based on the balance between the amount of water and the amounts of other oils and fats and the softeners such as liquid rubbers. Preferably, the amount of lanolin is from 5 to 40% and more preferably from 10 to 30%. Lanolin contained in an amount less than 5% is insufficient for stable retention of water, whereas when contained in an amount greater than 40%, it makes the adhesive base material unfavorably sticky.
Water is contained for the purposes of dissolving BPAA and providing the base material with a sense of "cooling effect". The amount of water is determined based on the balance between the amount of the active ingredient and the amount of lanolin and is preferably from 0.1 to 30% and more preferably from 0.3 to 20%.
If the amount of water is less than 0.1%, it becomes difficult not only to dissolve BPAA in the base material but also to provide the "cooling effect" to the plaster. In comparison, the adhesive preparation can hardly have required properties if the amount of water exceeds 30%.
The plaster of the present invention may optionally contain a solubilizer for BPAA, including amines and crotamiton. Examples of amine include monoethanolamine, diethanolamine, diisopropanolamine, triethanolamine, and triisopropanolamine. The amount of amine to be contained is preferably in the range from 1 to 15%.
In addition, the plaster of the present invention may further contain a softener for the purpose of providing the adhesive base material with a proper plasticity. Aside from the above-described lanolin component, examples of the softener include liquid rubbers, liquid paraffin, and fatty acid esters including isopropyl myristate. The amount of the softener to be used is preferably from 5 to 50% and more preferably from 10 to 45%.
Less than 5% of the softener is insufficient to provide sufficient plasticity to the adhesive base material. In such a case, the base material becomes too hard to be spread. In comparison, the softener, if contained in an amount exceeding 50%, makes the adhesive base material unfavorably sticky and brings about unfavorable situations such as the base material remaining on the surface to which it is applied after the plaster has been removed, or the base material coming out from the edges of the backing.
The amount of BPAA for serving as the active ingredient in the plaster of the present invention is preferably from 0.5 to 8%
and more preferably from 2 to 6%. The amount of BPAA that is less than 0.5% is insufficient to elicit pharmacological effects of BPAA, whereas if the amount exceeds 8%, unfavorable situations arise, such as crystallizing of BPAA.
Aside from the above-described components, the adhesive base material of the present invention may contain a pharmaceutically acceptable absorption enhancer, refrigerant, preservative, bactericide, pigment and other pharmaceutically acceptable agents as desired.
Using the above-described adhesive components, the plaster of the present invention can be manufactured, for example, through the following process.
For example, SIS, the adhesive resin, the antioxidant, lanolin, and the softener are melted, mixed, and kneaded in a kneader heated to about 150 C to obtain the adhesive base material, which is then cooled to 80 to 100 C by air or water.
Subsequently, warm water, together with a BPAA solution (aqueous) to serve as the active ingredient solution, is added gradually to the adhesive base material under stirring. The resulting adhesive base material is spread on the liner to a predetermined thickness, and then, laminated with the backing.
Then, the backing thus obtained is cut into desired size to produce the plaster of the present invention.
Alternatively, the adhesive base material may be prepared in a separate container and is stored into block forms. A required amount of the block forms is then melted at 80 to 100 C and mixed with water and the active ingredient solution.
If the temperature of the adhesive base material exceeds 100 C during addition of the aqueous solution of the active ingredient and water, water is brought to boiling and evaporates, and as a result, the amount of water in the plaster is significantly reduced. In comparison, if the temperature is lower than 80 C, the adhesive base material becomes so viscous that it is difficult to stir the mixture during the addition of the aqueous solution of the active ingredient. This prevents uniform dispersion of the active ingredient.
Examples The present invention will be further illustrated by the following examples. It is to be understood that the present invention is not limited to these examples. Details may be deleted, added, or substituted as it is deemed to be appropriate, so long as the pharmacological activities of the plaster of the present invention is not changed. Such changes are also covered within the technical scope of the present invention.
Examples 1 to 8 Adhesive base material with formulations shown in Tables 1 and 2 below were prepared.
A sheet of polyester film treated with silicone was used to serve as a liner, and a piece of fabric made from polyester fiber was used to serve as a backing for each adhesive base material.
The amount of each adhesive base material coated was 100g/m2.
Table 1: Formulations of adhesive base material containing BPAA
Materials Ex. 1 Ex. 2 Ex. 3 Ex. 4 SIS 14.0 18.0 16.0 17.0 Saturated alicyclic petroleum resin 25.0 - - -Rosin ester resin - 22.0 - -Terpene resin - - 24.0 25.0 Polybutene - - 7.0 19.0 Liquid paraffin 13.0 6.0 17.0 8.0 Polyethyleneglycol-400 - - 10.0 5.0 Dibutylhydroxytoluene 1.0 1.0 1.0 1.0 Lanolin 24.0 25.0 10.0 10.0 Purified water 9.0 9.0 1.0 1.0 Purified water (solvent for the BPAA) 1.0 1.0 1.0 1.0 Diisopropanolamine 5.0 5.0 5.0 5.0 Crotamiton 2.5 2.5 2.5 2.5 BPAA 5.0 5.0 5.0 5.0 1-menthol 0.5 0.5 0.5 0.5 Isopropyl myristate - 5.0 - -Table 2: Formulations of adhesive base material containing BPAA
Materials Ex. 5 Ex. 6 Ex. 7 Ex. 8 SIS 16.0 10.0 30.0 10.0 Terpene resin 24.0 35.0 15.0 18.0 Polybutene 6.0 12.0 16.5 -Liquid paraffin - 10.5 5.0 -Polyethyleneglycol-400 - 1.0 - -Dibutylhydroxytoluene 1.0 1.0 1.0 1.0 Lanolin 25.0 5.0 10.0 40.0 Purified water 9.0 4.0 4.0 29.0 Purified water (solvent for BPAA) 1.0 1.0 1.0 1.0 Diisopropanolamine 10.0 3.0 5.0 0.5 Crotamiton 2.5 2.0 2.0 -BPAA 5.0 5.0 5.0 0.5 1-menthol 0.5 0.5 0.5 -Cetyl alcohol - 10.0 5.0 -Comparative Examples 1 to 4 As Comparative Examples, external plaster using water-free ----- - ------hot melted type adhesives base material and commercially available acrylic acid ester adhesives were prepared. Formulation for each Comparative Example is shown in Table 3 below.
Table 3: Formulations of adhesive base material for Comparative Exam les Materials Comp. 1 Comp. 2 Comp. 3 Comp. 4 SIS 18.0 20.0 - -Terpene resin 29.0 31.0 - -Polybutene 15.0 15.0 - -Liquid paraffin 9.0 15.0 - -Polyethyleneglycol-400 5.0 5.0 5.0 5.0 Dibutylhydroxytoluene 1.0 1.0 - -Acrylic adhesive A *1 - - 72.0 -Acrylic adhesive B *2 - - - 72.0 Lanolin 10.0 10.0 10.0 Diisopropanolamine 5.0 5.0 5.0 5.0 Crotamiton 2.5 2.5 2.5 2.5 BPAA 5.0 5.0 5.0 5.0 1-menthol 0.5 0.5 0.5 0.5 *1: 2-ethylhexyl acrylate / vinyl acetate copolymer (commercially available) *2: 2-ethylhexyl acrylate / vinyl pyrrolidone copolymer (commercially available) Test Example 1: Drug Permeability Test Using a commercially available aqueous BPAA plaster (cataplasm) as a control, above-prepared plasters of Examples and Comparative Examples were tested for the ability to permeate the drug component in the in vi tro skin permeability tests.
Methods:
Using a scalpel and scissors, a piece of abdominal skin was cut from a hairless rat and was mounted on a vertically placed Franz diffusion cell with the receptor compartment filled with saline. Warm water with a temperature of about 35 C was circulated through the jacket of the cell.
The above-prepared plasters were each applied to the skin of hairless rat, and the receptor solution was sampled over time for each plaster. The amount of the drug permeated in 24 hours was determined by HPLC.
Results:
The results of the tests are shown in Table 4. For the commercially available aqueous BPAA plaster (cataplasm) serving as the control, the amount of the permeated drug was 66.Oig/cm2.
Table 4: Results of rat skin permeability test Plaster No. Ex. 1 Ex. 2 Ex. 3 Ex. 4 ---- ---------------------------------- -----------------Amount permeated ig/cm2 58.2 74.6 62.4 81.5 Plaster No Ex. 5 Ex. 6 Ex. 7 Ex. 8 ---- -----------------------------------------------------Amount permeated i.g/cm2 65.8 55.3 84.2 65.0 Plaster No Comp. 1 Comp. 2 Comp. 3 Comp. 4 --- -------- ----- ----Amount permeated ig/cm2 29.8 21.5 43.7 31.6 As can be seen from the results of Table 4 above, the plaster of Examples of the present invention each exhibited higher skin permeability than the plaster of Comparative Examples. This indicates that the plaster of the present invention has an improved releasability of the drug.
Test Example 2: Stability Test The above-prepared plasters of Examples and Comparative Examples were each placed in a polyethylene-aluminum bag, were stored for 6 months at 40 C, and were then examined for the presence of crystal deposition.
No crystal deposition was observed on the plasters of Examples, whereas crystals formed on the plasters of Comparative Examples as early as after 1 month, causing the plasters to remain stuck to the liner or significantly reducing the adhesion. No decrease was observed in the amount of the active ingredient (BPAA) in any of the preparations.
The presence or the absence of crystal deposition on the plasters observed after the storage period was shown in Tables 5 through 7, with the results of the adhesive strength of the plasters.
The adhesive strength (unit = g/25mm) was measured by peeling the plaster from a Bakelite plate at 1800 angles.
Table 5: Results of stability test (Examples 1 to 4) Ex. 1 Ex. 2 Ex. 3 Ex. 4 Initial _ _ Crystal _ _ _ _None _ _ _ _ _None_ _ _ _ _None_ _ _ _None_ _ (after production) Adhesive stren th 780 890 540 690 40 C Crystal None None None None !--------- ------------ --------------- ------------- -------------1 month Adhesive stren th 750 870 610 710 40 C Crystal None None None None 3 months --Adhesive -- 760 890 590 ---- 680 stren th 40 C Crystal None None None None 6 months Adhesive-- -740 ----790-----620 ----690--stren strength Table 6: Results of stability test (Examples 5 to 8) Ex. 5 Ex. 6 Ex. 7 Ex. 8 Initial Crystal _ _ _ None _ _ _ _ _None _ _ _ _None_ _ _ _None_ _ (after production) Adhesive 750 480 360 100 stren th 40 C Crystal None __ None __ None __ None _ F_-_-_-_-_ _-_-_-_-_ _-_-_-_-_-_-_ _-_-_-_-_-_ _--_-_-_-_ 1 month Adhesive stren th 770 500 410 120 40 C Crystal None None None None r --Adhesive ---------------------------3 months stren th 730 490 400 90 40 C Crystal None None None None months --Adhesive-- --750 ----- 480 ----- 390 -----90 --6 stren th Table 7: Results of stability test (Comparative Examples 1 to 4) Comp. 1 Comp. 2 Comp. 3 Comp. 4 Initial Crystal _ _ _None _ None _ _ None _ _ None _ ----- -- ------ ----------- ------------ ----------(after production) Adhesive stren th 2340 1780 2540 1520 40 C Crystal formed formed formed Formed - -Adh --- -------------- ------------- --------------- --------------1 month esive stren th 1580 320 410 280 400 C Crystal _ _f_ormed_ _ _f_ormed_ _ _ _f_ormed_ _ _ F_orme_d_ 3 months Adtiesive stren th 1460 380 340 250 40 C Crystal formed _ formed __ formed __ Formed_ - - - - ----------- ------------ ----------6 months Adhesive 1390 350 390 280 stren th 11 As can be seen from the results of Tables 5 to 7, BPAA did not crystallize from the layer of the adhesive base material in any of the plaster of Examples of the present invention. Also, little change was observed in the adhesive strength in the plaster of Examples.
In contrast, deposition of BPAA crystals was observed in each of the plaster of Comparative Examples. These plaster lost adhesive strength significantly over time, failing to maintain their initial adhesion strength.
INDUSTRIAL APPLICABILITY
As mentioned above, the plaster for external use of the present invention, which is obtained by dissolving BPAA into an aqueous hot melted type adhesive base material comprising as essential components a styrene-isoprene-styrene block copolymer, an adhesive resin, an antioxidant, lanolin, and water, is advantageous in that it exhibits a good drug stability as well as a good drug releasability over time and the adhesion of the plaster is not decreased over time.
Claims (18)
1. An analgesic and anti-inflammatory external plaster which comprises:
a) 4-biphenylyl acetic acid (BPAA); and b) an aqueous hot melt type adhesive base material comprising the following components in t by weight based on a total weight of BPAA and the aqueous hot melt type adhesive base material:
10-30% by weight of a styrene-isoprene-styrene block copolymer (SIS);
15-35% by weight of an adhesive resin;
0.1-2% by weight of an antioxidant;
5-40% by weight of lanolin;
5-50% by weight of a softener; and water, wherein 4-biphenylyl acetic acid is dissolved into the aqueous hot melt type adhesive base material.
a) 4-biphenylyl acetic acid (BPAA); and b) an aqueous hot melt type adhesive base material comprising the following components in t by weight based on a total weight of BPAA and the aqueous hot melt type adhesive base material:
10-30% by weight of a styrene-isoprene-styrene block copolymer (SIS);
15-35% by weight of an adhesive resin;
0.1-2% by weight of an antioxidant;
5-40% by weight of lanolin;
5-50% by weight of a softener; and water, wherein 4-biphenylyl acetic acid is dissolved into the aqueous hot melt type adhesive base material.
2. The external plaster according to claim 1, wherein water is contained in an amount of 0.1 to 30% by weight.
3. The external plaster according to claim 1 or 2, wherein 4-biphenylyl acetic acid is contained in an amount of 0.5 to 8% by weight based on the total weight of BPAA and the aqueous hot melt type adhesive base material.
4. The external plaster according to claim 1 or 2, wherein 4-biphenylyl acetic acid is contained in an amount of 2 to 6% by weight based on the total weight of BPAA and the aqueous hot melt type adhesive base material.
5. The external plaster according to any one of claims 1 to 4, wherein the SIS is contained in an amount of 15 to 25% by weight.
6. The external plaster according to any one of claims 1 to 5, wherein the SIS has a styrene/rubber ratio of 14/86.
7. The external plaster according to any one of claims 1 to 6, wherein the adhesive resin is contained in an amount of 20 to 30% by weight.
8. The external plaster according to any one of claims 1 to 7, wherein the adhesive resin is an aromatic resin, an aliphatic resin, an alicyclic petroleum resin, a rosin resin, a rosin ester resin, a terpene resin or a mixture thereof.
9. The external plaster according to any one of claims 1 to 8, wherein lanolin is contained in an amount from 10 to 30% by weight.
10. The external plaster according to any one of claims 1 to 9, wherein the antioxidant is dibutylhydroxytoluene, pentaerythrityl-tetrakis[3-(3,5-di-t-butyl-4-hydroxyphenyl)]proprionate or tocopherol acetate.
11. The external plaster according to any one of claims 1 to 10, which further comprises a lining, wherein the adhesive base material containing 4-biphenylyl acetic acid is coated on the lining.
12. The external plaster according to claim 11 which is laminated with a backing.
13. The external plaster according to any one of claims 1 to 12 for relieving pain and alleviating inflammation from osteoarthritis, muscle- and fascia-related lumbago, periarthritis humeroscapularis, tendinitis, tenosynovitis, peritendinitis, external humeral epicondylitis, sore muscle, or post-traumatic swelling and pain.
14. A process for producing an analgesic and anti-inflammatory external plaster containing 4-biphenylyl acetic acid (BPAA), which process comprises the steps of:
melting and kneading 10-30% by weight of a styrene-isoprene-styrene block copolymer, 15-35% by weight of an adhesive resin, 0.1-2% by weight of an antioxidant, 5-40% by weight of lanolin, and 5-50% by weight of a softener to form an adhesive base; and adding water and an aqueous solution of 4-biphenylyl acetic acid to the adhesive base at a temperature of 80 to 100°C, while stirring, to form an adhesive base material containing 4-biphenylyl acetic acid, wherein the % by weight is based on a total weight of BPAA and the adhesive base material.
melting and kneading 10-30% by weight of a styrene-isoprene-styrene block copolymer, 15-35% by weight of an adhesive resin, 0.1-2% by weight of an antioxidant, 5-40% by weight of lanolin, and 5-50% by weight of a softener to form an adhesive base; and adding water and an aqueous solution of 4-biphenylyl acetic acid to the adhesive base at a temperature of 80 to 100°C, while stirring, to form an adhesive base material containing 4-biphenylyl acetic acid, wherein the % by weight is based on a total weight of BPAA and the adhesive base material.
15. The process according to claim 14 which further comprises:
coating the adhesive base material on a liner; and laminating the adhesive base material on the liner with a backing.
coating the adhesive base material on a liner; and laminating the adhesive base material on the liner with a backing.
16. The process according to claim 15 which further comprises cutting the external plaster thus obtained into a desired size.
17. An analgesic and anti-inflammatory external plaster containing 4-biphenylyl acetic acid (BPAA), which is obtained by a process comprising the steps of:
melting and kneading 10-30% by weight of a styrene-isoprene-styrene block copolymer, 15-35% by weight of an adhesive resin, 0.1-2% by weight of an antioxidant, 5-40% by weight of lanolin, and 5-50% by weight of a softener to form an adhesive base material;
adding water and an aqueous solution of BPAA to the adhesive base material at a temperature of 80 to 100°C, while stirring, to form an adhesive base material containing BPAA;
coating the adhesive base material on a liner;
attaching the liner to a base cloth; and cutting the base cloth to a desired size, wherein the % by weight is based on a total weight of BPAA and the adhesive base material.
melting and kneading 10-30% by weight of a styrene-isoprene-styrene block copolymer, 15-35% by weight of an adhesive resin, 0.1-2% by weight of an antioxidant, 5-40% by weight of lanolin, and 5-50% by weight of a softener to form an adhesive base material;
adding water and an aqueous solution of BPAA to the adhesive base material at a temperature of 80 to 100°C, while stirring, to form an adhesive base material containing BPAA;
coating the adhesive base material on a liner;
attaching the liner to a base cloth; and cutting the base cloth to a desired size, wherein the % by weight is based on a total weight of BPAA and the adhesive base material.
18. The external plaster according to claim 17, wherein water is contained in an amount of 0.1 to 30% by weight.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP28134699A JP4676042B2 (en) | 1999-10-01 | 1999-10-01 | Topical analgesic / anti-inflammatory patch containing felbinac |
| PCT/JP2000/008440 WO2002043729A1 (en) | 1999-10-01 | 2000-11-29 | Analgesic and anti-inflammatory patches for external use containing 4-biphenylylylacetic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2397537A1 CA2397537A1 (en) | 2002-06-06 |
| CA2397537C true CA2397537C (en) | 2008-11-18 |
Family
ID=34878901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002397537A Expired - Fee Related CA2397537C (en) | 1999-10-01 | 2000-11-29 | External plaster containing 4-biphenylyl acetic acid |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20030088199A1 (en) |
| EP (1) | EP1342472B1 (en) |
| JP (1) | JP4676042B2 (en) |
| KR (1) | KR100757726B1 (en) |
| AT (1) | ATE345789T1 (en) |
| AU (1) | AU780735B2 (en) |
| CA (1) | CA2397537C (en) |
| DE (1) | DE60032032T2 (en) |
| DK (1) | DK1342472T3 (en) |
| ES (1) | ES2272337T3 (en) |
| TW (1) | TWI236904B (en) |
| WO (1) | WO2002043729A1 (en) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6300108B1 (en) * | 1999-07-21 | 2001-10-09 | The Regents Of The University Of California | Controlled electroporation and mass transfer across cell membranes |
| US6697670B2 (en) * | 2001-08-17 | 2004-02-24 | Minnesota Medical Physics, Llc | Apparatus and method for reducing subcutaneous fat deposits by electroporation with improved comfort of patients |
| US8251986B2 (en) * | 2000-08-17 | 2012-08-28 | Angiodynamics, Inc. | Method of destroying tissue cells by eletroporation |
| USRE42016E1 (en) | 2001-08-13 | 2010-12-28 | Angiodynamics, Inc. | Apparatus and method for the treatment of benign prostatic hyperplasia |
| US7130697B2 (en) * | 2002-08-13 | 2006-10-31 | Minnesota Medical Physics Llc | Apparatus and method for the treatment of benign prostatic hyperplasia |
| US6994706B2 (en) * | 2001-08-13 | 2006-02-07 | Minnesota Medical Physics, Llc | Apparatus and method for treatment of benign prostatic hyperplasia |
| JP2004277345A (en) * | 2003-03-17 | 2004-10-07 | Daikyo Yakuhin Kogyo Kk | Plaster and method for producing the same |
| US20050171574A1 (en) | 2003-12-24 | 2005-08-04 | The Regents Of The University Of California | Electroporation to interrupt blood flow |
| JP4443278B2 (en) * | 2004-03-26 | 2010-03-31 | テルモ株式会社 | Catheter with expansion body |
| US20060264752A1 (en) * | 2005-04-27 | 2006-11-23 | The Regents Of The University Of California | Electroporation controlled with real time imaging |
| US20060293725A1 (en) * | 2005-06-24 | 2006-12-28 | Boris Rubinsky | Methods and systems for treating fatty tissue sites using electroporation |
| US8114070B2 (en) * | 2005-06-24 | 2012-02-14 | Angiodynamics, Inc. | Methods and systems for treating BPH using electroporation |
| US20060293731A1 (en) * | 2005-06-24 | 2006-12-28 | Boris Rubinsky | Methods and systems for treating tumors using electroporation |
| MX2008000122A (en) * | 2005-06-30 | 2008-03-18 | Lg Electronics Inc | Method and apparatus for encoding and decoding an audio signal. |
| US20070156135A1 (en) * | 2006-01-03 | 2007-07-05 | Boris Rubinsky | System and methods for treating atrial fibrillation using electroporation |
| US7674249B2 (en) * | 2006-10-16 | 2010-03-09 | The Regents Of The University Of California | Gels with predetermined conductivity used in electroporation of tissue |
| US20080132884A1 (en) * | 2006-12-01 | 2008-06-05 | Boris Rubinsky | Systems for treating tissue sites using electroporation |
| WO2009121009A2 (en) * | 2008-03-27 | 2009-10-01 | The Regents Of The University Of California | Irreversible electroporation device for use in attenuating neointimal |
| US20100004623A1 (en) * | 2008-03-27 | 2010-01-07 | Angiodynamics, Inc. | Method for Treatment of Complications Associated with Arteriovenous Grafts and Fistulas Using Electroporation |
| US10117707B2 (en) | 2008-04-29 | 2018-11-06 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
| US9198733B2 (en) | 2008-04-29 | 2015-12-01 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for electroporation-based therapies |
| US9867652B2 (en) | 2008-04-29 | 2018-01-16 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds |
| US10245098B2 (en) | 2008-04-29 | 2019-04-02 | Virginia Tech Intellectual Properties, Inc. | Acute blood-brain barrier disruption using electrical energy based therapy |
| US9598691B2 (en) | 2008-04-29 | 2017-03-21 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation to create tissue scaffolds |
| US8992517B2 (en) * | 2008-04-29 | 2015-03-31 | Virginia Tech Intellectual Properties Inc. | Irreversible electroporation to treat aberrant cell masses |
| US11254926B2 (en) | 2008-04-29 | 2022-02-22 | Virginia Tech Intellectual Properties, Inc. | Devices and methods for high frequency electroporation |
| US10238447B2 (en) | 2008-04-29 | 2019-03-26 | Virginia Tech Intellectual Properties, Inc. | System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress |
| US11272979B2 (en) | 2008-04-29 | 2022-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
| US9283051B2 (en) | 2008-04-29 | 2016-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating a treatment volume for administering electrical-energy based therapies |
| US10702326B2 (en) | 2011-07-15 | 2020-07-07 | Virginia Tech Intellectual Properties, Inc. | Device and method for electroporation based treatment of stenosis of a tubular body part |
| US10272178B2 (en) | 2008-04-29 | 2019-04-30 | Virginia Tech Intellectual Properties Inc. | Methods for blood-brain barrier disruption using electrical energy |
| WO2009137800A2 (en) * | 2008-05-09 | 2009-11-12 | Angiodynamics, Inc. | Electroporation device and method |
| US9173704B2 (en) * | 2008-06-20 | 2015-11-03 | Angiodynamics, Inc. | Device and method for the ablation of fibrin sheath formation on a venous catheter |
| WO2010008834A2 (en) * | 2008-06-23 | 2010-01-21 | Angiodynamics, Inc. | Treatment devices and methods |
| US20100152725A1 (en) * | 2008-12-12 | 2010-06-17 | Angiodynamics, Inc. | Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation |
| US8753335B2 (en) * | 2009-01-23 | 2014-06-17 | Angiodynamics, Inc. | Therapeutic energy delivery device with rotational mechanism |
| WO2010093692A2 (en) * | 2009-02-10 | 2010-08-19 | Hobbs Eamonn P | Irreversible electroporation and tissue regeneration |
| WO2010118387A1 (en) * | 2009-04-09 | 2010-10-14 | Virginia Tech Intellectual Properties, Inc. | Integration of very short electric pulses for minimally to noninvasive electroporation |
| US11638603B2 (en) | 2009-04-09 | 2023-05-02 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
| US11382681B2 (en) | 2009-04-09 | 2022-07-12 | Virginia Tech Intellectual Properties, Inc. | Device and methods for delivery of high frequency electrical pulses for non-thermal ablation |
| USD630321S1 (en) | 2009-05-08 | 2011-01-04 | Angio Dynamics, Inc. | Probe handle |
| US8903488B2 (en) | 2009-05-28 | 2014-12-02 | Angiodynamics, Inc. | System and method for synchronizing energy delivery to the cardiac rhythm |
| US9895189B2 (en) | 2009-06-19 | 2018-02-20 | Angiodynamics, Inc. | Methods of sterilization and treating infection using irreversible electroporation |
| US20110118732A1 (en) | 2009-11-19 | 2011-05-19 | The Regents Of The University Of California | Controlled irreversible electroporation |
| EP2627274B1 (en) | 2010-10-13 | 2022-12-14 | AngioDynamics, Inc. | System for electrically ablating tissue of a patient |
| CN103269696B (en) | 2010-11-02 | 2015-04-01 | 帝国制药株式会社 | Felbinac-containing external patch |
| WO2012088149A2 (en) | 2010-12-20 | 2012-06-28 | Virginia Tech Intellectual Properties, Inc. | High-frequency electroporation for cancer therapy |
| US9078665B2 (en) | 2011-09-28 | 2015-07-14 | Angiodynamics, Inc. | Multiple treatment zone ablation probe |
| US9414881B2 (en) | 2012-02-08 | 2016-08-16 | Angiodynamics, Inc. | System and method for increasing a target zone for electrical ablation |
| JP6594901B2 (en) | 2014-05-12 | 2019-10-23 | バージニア テック インテレクチュアル プロパティース インコーポレイテッド | Selective modulation of intracellular effects of cells using pulsed electric fields |
| CN104262138B (en) * | 2014-08-22 | 2016-05-11 | 湖北美林药业有限公司 | A kind of felbinac compound and pharmaceutical composition thereof |
| WO2016100325A1 (en) | 2014-12-15 | 2016-06-23 | Virginia Tech Intellectual Properties, Inc. | Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment |
| CN106822049B (en) * | 2015-12-07 | 2020-10-20 | 北京乳凝创智生物技术研发中心（有限合伙） | Novel chemical medicine patch ketoprofen patch and preparation method thereof |
| US10905492B2 (en) | 2016-11-17 | 2021-02-02 | Angiodynamics, Inc. | Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode |
| US11607537B2 (en) | 2017-12-05 | 2023-03-21 | Virginia Tech Intellectual Properties, Inc. | Method for treating neurological disorders, including tumors, with electroporation |
| US11311329B2 (en) | 2018-03-13 | 2022-04-26 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for immunotherapy based treatments using non-thermal ablation techniques |
| US11925405B2 (en) | 2018-03-13 | 2024-03-12 | Virginia Tech Intellectual Properties, Inc. | Treatment planning system for immunotherapy enhancement via non-thermal ablation |
| US11950835B2 (en) | 2019-06-28 | 2024-04-09 | Virginia Tech Intellectual Properties, Inc. | Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5374537A (en) | 1976-12-13 | 1978-07-03 | Dai Ichi Kogyo Seiyaku Co Ltd | Softener for pressure-sensitive adhesive |
| JPS54101420A (en) * | 1978-01-25 | 1979-08-10 | Nitto Electric Ind Co Ltd | Poultice and its preparation |
| JPS5826888B2 (en) * | 1979-03-26 | 1983-06-06 | 日東電工株式会社 | poultice |
| JPS593966B2 (en) * | 1979-09-04 | 1984-01-27 | 日東電工株式会社 | patch |
| US4398985A (en) * | 1980-02-08 | 1983-08-16 | Kimberly-Clark Corporation | Releasable, self-detackifying laminate construction |
| JPH0614957B2 (en) * | 1983-06-20 | 1994-03-02 | 帝国製薬株式会社 | Tape-shaped hydrous patch and method for producing the same |
| JP3723229B2 (en) * | 1991-03-12 | 2005-12-07 | 武田薬品工業株式会社 | External patch |
| JP3541849B2 (en) * | 1991-04-19 | 2004-07-14 | 久光製薬株式会社 | Anti-inflammatory analgesic patch |
| JPH062253A (en) * | 1992-06-18 | 1994-01-11 | Barudan Co Ltd | Embroidery hoop |
| JPH0624969A (en) * | 1992-07-09 | 1994-02-01 | Teikoku Seiyaku Co Ltd | Ketoprofen-containing cataplasm |
| AU722937B2 (en) * | 1996-12-06 | 2000-08-17 | Hisamitsu Pharmaceutical Co., Inc. | Plaster containing felbinac |
| US6471984B1 (en) * | 1998-01-14 | 2002-10-29 | Hisamitsu Pharmaceutical Co., Inc. | Cataplasm and tape-aid containing a plasticizer |
| US6946514B2 (en) * | 2000-11-29 | 2005-09-20 | Teikoko Seiyaku Co. Ltd. | Adhesive preparation for external use |
-
1999
- 1999-10-01 JP JP28134699A patent/JP4676042B2/en not_active Expired - Fee Related
-
2000
- 2000-11-29 DK DK00978012T patent/DK1342472T3/en active
- 2000-11-29 US US10/203,276 patent/US20030088199A1/en not_active Abandoned
- 2000-11-29 ES ES00978012T patent/ES2272337T3/en not_active Expired - Lifetime
- 2000-11-29 KR KR1020027009683A patent/KR100757726B1/en not_active IP Right Cessation
- 2000-11-29 AT AT00978012T patent/ATE345789T1/en not_active IP Right Cessation
- 2000-11-29 EP EP00978012A patent/EP1342472B1/en not_active Expired - Lifetime
- 2000-11-29 DE DE60032032T patent/DE60032032T2/en not_active Expired - Lifetime
- 2000-11-29 AU AU15545/01A patent/AU780735B2/en not_active Ceased
- 2000-11-29 CA CA002397537A patent/CA2397537C/en not_active Expired - Fee Related
- 2000-11-29 WO PCT/JP2000/008440 patent/WO2002043729A1/en active IP Right Grant
- 2000-12-05 TW TW089125895A patent/TWI236904B/en not_active IP Right Cessation
-
2005
- 2005-09-06 US US11/218,568 patent/US7276641B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1342472A1 (en) | 2003-09-10 |
| DE60032032T2 (en) | 2007-05-31 |
| ATE345789T1 (en) | 2006-12-15 |
| KR100757726B1 (en) | 2007-09-11 |
| EP1342472A4 (en) | 2005-09-28 |
| DK1342472T3 (en) | 2007-01-15 |
| WO2002043729A1 (en) | 2002-06-06 |
| ES2272337T3 (en) | 2007-05-01 |
| US7276641B2 (en) | 2007-10-02 |
| AU1554501A (en) | 2002-06-11 |
| AU780735B2 (en) | 2005-04-14 |
| JP4676042B2 (en) | 2011-04-27 |
| TWI236904B (en) | 2005-08-01 |
| US20060015054A1 (en) | 2006-01-19 |
| KR20020079811A (en) | 2002-10-19 |
| EP1342472B1 (en) | 2006-11-22 |
| US20030088199A1 (en) | 2003-05-08 |
| DE60032032D1 (en) | 2007-01-04 |
| JP2001097857A (en) | 2001-04-10 |
| CA2397537A1 (en) | 2002-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2397537C (en) | External plaster containing 4-biphenylyl acetic acid | |
| CA2786233C (en) | Anti-inflammatory analgesic adhesive patch for external use | |
| CA2414239C (en) | Analgesic anti-inflammatory patch for topical application | |
| CA2525470C (en) | External patch containing estrogen and/or progestogen | |
| JP4181232B2 (en) | Diclofenac sodium-containing oily external patch preparation | |
| US8246982B2 (en) | Pressure-sensitive adhesives based on ethylene-vinyl acetate copolymers and adhesive resins, for medical application purposes | |
| JP5280678B2 (en) | External patch containing flurbiprofen | |
| JP4302835B2 (en) | External patch | |
| KR100721748B1 (en) | Patch containing 4-biphenylacetic acid | |
| CA2397546C (en) | External plaster | |
| JP5431969B2 (en) | Fentanyl-containing external patch | |
| JP7399633B2 (en) | Method for manufacturing transdermal preparations | |
| JP5564241B2 (en) | Percutaneous absorption preparation containing felbinac | |
| JP2004224701A (en) | External cataplasm | |
| RU2382641C2 (en) | External fluorbiprophene-containing plaster |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20161129 |